Check out your Company Bowl for anonymous work chats.
Exciting news! Our very own Noura Abul-Husn, 23andMe's VP of Genomic Health, wrote an insightful article in STAT on how direct-to-consumer genetic testing has brought both challenges and opportunities for today's healthcare providers. “...more is needed to scale genetics knowledge broadly across health care specialties to ensure that genetic information is interpreted and used appropriately in routine clinical care and to usher in the long-promised new age of personalized health care," wrote Dr. Abul-Husn.
Since the start of the pandemic, 23andMe scientists have utilized our large database of consented research participants to look at COVID-19. From the impact of blood type on susceptibility to the virus to differences in vaccine reactions, our scientists have learned a lot. We are now turning our focus to better understand long COVID and the long-term impacts of the virus.
Congratulations to our CEO and Co-Founder Anne Wojcicki for being an amazing leader and getting 23andMe listed on The Org's “Companies Founded by Women That Are Breaking Barriers.” #WomensHistoryMonth
Meet Sophia R. Majeed, Principal Clinical Scientist at 23andMe. Sophia is a key member of our Therapeutics team and provides clinical development support for our oncology programs. Her role involves reviewing and discussing different clinical and nonclinical data to help guide our team’s drug development strategy and execute our day-to-day deliverables. One of Sophia’s favorite and most gratifying parts of her job is when she sees our scientific discoveries have a meaningful impact on people’s lives. “It serves as an important reminder of why we all work so hard.” In addition to her work at 23andMe, Sophia co-leads the 23andShe Employee Resource Group (ERG) and is a member of other ERGs, including 23andWhole and APIC. She is proud of the cultural shifts she has seen due to the work being done by various ERGs.
We are excited to share our inaugural environmental, social and governance (ESG) report. This report outlines our strategic framework and current initiatives for ensuring ethical management, promoting a diverse and equitable culture, and implementing sustainable operations. “23andMe is passionate about understanding the genetic code of life, translating that information for all, and using it to improve the health and wellbeing of the world. As each customer discovers their DNA, we believe we have an important role in fostering meaningful connections throughout the world. 23andMe is committed to making our product, our community, and our company diverse, equitable, and inclusive,” said Anne Wojcicki, our CEO and Co-Founder.
No matter who you are or where you come from, you are welcome to join us on this spectacular journey of learning more about your genetics.
In honor of Women’s History Month, the 23andMe Speaker Series and our 23andShe Employee Resource Group hosted a panel with Claire Curtin and Roxy Wolosenko, producers of The Sims video game series. During the event they discussed how The Sims was created, their experience in software development as women, job sharing, and life after The Sims. Claire and Roxy also answered employee questions and provided advice for women in the workplace.
Meet Mary-Padgett Hawkins (MP), one of our talented Product Managers at 23andMe, who works on both Lemonaid Health and 23andMe initiatives. MP’s role involves identifying the biggest needs of our customers and business, then working with her great and resourceful team to address those needs by improving our website and products. MP’s favorite part about working at 23andMe is learning something new every day. She appreciates the company’s ambitious dreams and driven people who are ready to change the future of healthcare. Outside of work, MP loves spending time in nature. Being outside was a huge part of her life growing up, and it continues to be core to who she is and how she spends her free time. Hiking, skiing, and kayaking are some of her favorite fresh-air, head-clearing hobbies.
In support of #LpaAwarenessDay, we’ve teamed up with Novartis US to help increase awareness of Lipoprotein(a) (Lp(a)). Roughly one in five people have high levels of Lp(a), which conveys a 2-4 times higher risk for heart disease. And the level of Lp(a), which can be detected through a blood test, is almost entirely determined by genes. #KnowLpa
We released a new 23andMe+ Genetic Health Risk Report* on HOXB13-related hereditary prostate cancer. This report tells 23andMe+ members if they have the G84E variant in the HOXB13 gene. This variant is associated with a 33–53% chance of developing prostate cancer by age 80, compared to about a 13% lifetime risk for the general population. Keep in mind that only people with a prostate are at risk of developing prostate cancer. Although people without a prostate are not at risk, they still have access to this report in order to provide important information they can share with their family members. *Reports only one genetic variant in the HOXB13 gene associated with an increased risk of developing prostate cancer. Cannot diagnose any disease or tell you about your overall risk of developing a disease. Not a substitute for visits to your doctor or recommended screenings. Results should be confirmed by your doctor before taking any medical action. For adults only. Visit https://lnkd.in/gvRdFg3A for additional important limitations regarding this test.
